Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 29, 2025
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune …
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will …
New study shows significant decline in men’s mental health; half lack sufficient social support
GlobeNewswire
·
May 29, 2025
Stress and depression risk increase for Canadian men One in two men lack sufficient social support networks Canadian Men’s Health Foundation launches #NeverAlone campaign for Men’s Health Month in June VANCOUVER, British Columbia, May 29, 2025 (GLOBE …
SweetWater Brewing and Zoo Atlanta Celebrate 18 Years of Collaboration with a Special Edition Beer
GlobeNewswire
·
May 29, 2025
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY) is thrilled to extend their partnership …
DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District
GlobeNewswire
·
May 29, 2025
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, is pleased to announce the strategic …
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewswire
·
May 29, 2025
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …
Immuneering to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that …
Safety Shot Reminds Shareholders to Vote Their Proxy at the Upcoming Annual Shareholder Meeting
GlobeNewswire
·
May 29, 2025
SCOTTSDALE, Ariz., May 29, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, reminds shareholders that its Annual Shareholders’ Meeting will be held on Thursday, …
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire
·
May 29, 2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE …
Digital Landia, LLC, in Cooperation with PetVivo Holdings, Inc., Announces Invite-Only MVP Availability Amid Stress-Testing & Debugging Phase
GlobeNewswire
·
May 29, 2025
MIAMI, FL, May 29, 2025 (GLOBE NEWSWIRE) -- Digital Landia, LLC (“Digital Landia”), owner of Agentic.Pet, an autonomous pet artificial intelligence ecosystem, in cooperation with PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly owned …
MDaudit and Streamline Health Announce Definitive Merger Agreement
GlobeNewswire
·
May 29, 2025
The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable …
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
·
May 29, 2025
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at …
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
GlobeNewswire
·
May 29, 2025
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
GlobeNewswire
·
May 29, 2025
NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical …
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today …
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire
·
May 29, 2025
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies …
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …